Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.57 |
| ▸ | DRD3 | P35462 | 8/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | DRD4 | P21917 | 6/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318329 | 1.00 | DRD2 (0.57) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL6954331 | 0.82 | DRD2 (0.51) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL6954327 | 0.82 | DRD2 (0.51) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL6958607 | 0.82 | DRD2 (0.51) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL4857120 | 0.81 | CA1 (0.45) | CA1CA2MTNR1AMTNR1B | |
| SCHEMBL6953263 | 0.81 | CA1 (0.45) | CA1CA2MTNR1AMTNR1B | |
| SCHEMBL7778680 | 0.80 | CHRM2 (0.57) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL7778683 | 0.80 | CHRM2 (0.57) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL9017272 | 0.79 | DRD2 (0.58) | DRD2DRD3CA1CA2ACHE | |
| SCHEMBL9017312 | 0.78 | DRD2 (0.50) | DRD2DRD3CA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-8097641-B2 | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-04-29 | — | — | US | disclosed |
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | HTR7, HTR2C, HTR6 | DRD2 264/4885DRD3 370/4885CA1 3900/4885 |
| US-20100105684-A1 | HETEROCYCLYL-SUBSTITUTED-TETRAHYDRO-NAPHTHALEN-AMINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HNMT, NNT, NQO1 | DRD2 1527/4885DRD3 1739/4885CA1 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.